Articles from PMGC Holdings Inc.

NEWPORT BEACH, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the “Company” or “PMGC”) (Nasdaq: ELAB) is pleased to announce that its operating investment division, PMGC Capital LLC, has begun building its portfolio with strategic investments in the fire prevention technology and the U.S. uranium energy market. These initial investments underscore the Company's commitment to financing innovation in essential industries with significant growth opportunities.

NEWPORT BEACH, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB), today announced that its subsidiary, Northstrive Biosciences Inc. (“Northstrive Biosciences”), has executed a research agreement (“Research Agreement”) with a leading preclinical contract research organization (“CRO”) specializing in metabolic disorders. This Research Agreement will support a preclinical study carried out by the CRO and designed to evaluate EL-32, a novel engineered probiotic, as a monotherapy and in combination with the GLP-1 receptor agonist semaglutide, focusing on its impact on glycemic control and body composition in diet-induced obese (DIO) mice. Pursuant to the research agreement, within three months of completion of this study, the CRO will provide results of this study to Northstrive Biosciences and deliver a report to Northstrive Biosciences describing the work envisaged in the Research Agreement.

NEWPORT BEACH, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB) a diversified holding company today announced it has entered into a warrant inducement agreement with existing institutional investors for the exercise of certain outstanding Series A warrants that the Company issued on September 24, 2024. Pursuant to the warrant inducement agreement, the investors have agreed to exercise the outstanding warrants to purchase an aggregate of 969,385 shares of the Company's common stock at an amended exercise price of $2.00. The gross proceeds from the exercise of the warrants are expected to be approximately $1.9 million, prior to deducting placement agent fees and estimated offering expenses.

Northstrive Biosciences Inc. was invited to present EL-22, a novel myostatin asset aimed at preserving muscle while on weight loss treatments, at the UCLA Obesity Symposium called Anti-Obesity Treatments: Challenges and Emerging Solutions, organized by UCLA Metabolism Theme. This is an invite only event that brings together industry leading voices in the obesity space.

Strategic Divestment Reduces Cash Burn and Enhances Operational Efficiency

NEWPORT BEACH, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB) is pleased to announce the renaming of its wholly owned subsidiaries as part of a strategic effort to better align with the company's evolving business focus as a diversified holding company. Effective immediately, the following name changes have taken place:

Divestiture Highlights Strategic Plans on Potential High-Impact Acquisitions

NEWPORT BEACH, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc (NASDAQELAB), a diversified holding company, and Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced that it entered into a definitive purchase agreement with PMGC Holdings Inc. (formerly Elevai Labs Inc.) and its wholly owned subsidiary, Elevai Skincare Inc. (“Elevai”), to acquire the assets related to its skincare and haircare business (the “Acquisition”).